Literature DB >> 19593580

Driving simulator performance and psychomotor functions of schizophrenic patients treated with antipsychotics.

Alexander Brunnauer1, Gerd Laux, Sarah Zwick.   

Abstract

The objective of the study is to compare schizophrenic inpatients under antipsychotic monotherapy regarding simulated driving behaviour and psychomotor functions related to driving ability. Schizophrenic inpatients (n = 80) were tested before discharge to outpatient treatment. Data were collected with the computerized Act & React Testsystem and the Wiener Testsystem measuring visual perception, reaction time, attention, vigilance and stress-tolerance. Besides, patients underwent various driving simulations on a static driving simulator (FT-SR 200). Before discharge to outpatient treatment, about 25% of schizophrenic patients must be considered as severely impaired with respect to driving skills. Differences between treatment groups could be shown both in psychomotor measures and in driving simulator performance with a better test performance of patients treated with atypical antipsychotics. Controlling for age, psychopathologic symptoms and extrapyramidal signs, differences in psychomotor measures were most pronounced in concentration and vigilance. As mental disorders itself pose an increased risk of accidents, counselling patients with respect to differential effects of antipsychotic treatment is of great relevance. In addition to psychomotor tests computer-simulated driving seems to be a useful tool in assessing traffic safety under pharmacologic treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593580     DOI: 10.1007/s00406-009-0014-4

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  30 in total

1.  [Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].

Authors:  S Dittert; M Soyka; C Winter; H J Möller
Journal:  Fortschr Neurol Psychiatr       Date:  1999-11       Impact factor: 0.752

2.  Effects of quetiapine on cognitive functions in schizophrenia.

Authors:  Berna Binnur Kivircik Akdede; Köksal Alptekin; Arzu Kitiş; Haluk Arkar; Yildiz Akvardar
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-12-24       Impact factor: 5.067

3.  A statistical study on the relationship between mental illness and traffic accidents--a pilot study.

Authors:  R C Eelkema; J Brosseau; R Koshnick; C McGee
Journal:  Am J Public Health Nations Health       Date:  1970-03

4.  Antidepressants and driving ability: results from a clinical study.

Authors:  Alexander Brunnauer; Gerd Laux; Elisabeth Geiger; Michael Soyka; Hans-Jürgen Möller
Journal:  J Clin Psychiatry       Date:  2006-11       Impact factor: 4.384

5.  Does cognitive function improve with quetiapine in comparison to haloperidol?

Authors:  Dawn I Velligan; John Newcomer; Joseph Pultz; John Csernansky; Anne L Hoff; Roderick Mahurin; Alexander L Miller
Journal:  Schizophr Res       Date:  2002-01-15       Impact factor: 4.939

6.  Accidents among schizophrenic outpatients.

Authors:  M J Edlund; C Conrad; P Morris
Journal:  Compr Psychiatry       Date:  1989 Nov-Dec       Impact factor: 3.735

7.  Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.

Authors:  Robert M Bilder; Robert S Goldman; Jan Volavka; Pal Czobor; Matthew Hoptman; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph McEvoy; Michal Kunz; Miranda Chakos; Thomas B Cooper; Terri L Horowitz; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2002-06       Impact factor: 18.112

8.  Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic.

Authors:  Martin Hambrecht; Michael Lammertink; Joachim Klosterkötter; Eveline Matuschek; Ralf Pukrop
Journal:  Br J Psychiatry Suppl       Date:  2002-09

9.  Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Authors:  Michael Riedel; Ilja Spellmann; Martin Strassnig; Anette Douhet; Sandra Dehning; Markus Opgen-Rhein; Rosamaria Valdevit; Rolf R Engel; Nikolaus Kleindienst; Norbert Müller; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270

10.  Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

Authors:  B Gallhofer; U Bauer; S Lis; S Krieger; H Gruppe
Journal:  Eur Neuropsychopharmacol       Date:  1996       Impact factor: 4.600

View more
  9 in total

1.  A randomized, crossover, placebo-controlled clinical trial to assess the sensitivity of the CRCDS Mini-Sim to the next-day residual effects of zopiclone.

Authors:  Arthur A Simen; Cynthia Gargano; Jang-Ho Cha; Melissa Drexel; An Bautmans; Ingeborg Heirman; Tine Laethem; Thomas Hochadel; Lien Gheyle; Kim Bleys; Chan Beals; Aubrey Stoch; Gary G Kay; Arie Struyk
Journal:  Ther Adv Drug Saf       Date:  2015-06

2.  Antipsychotic-induced somnolence in mothers with schizophrenia.

Authors:  Mary V Seeman
Journal:  Psychiatr Q       Date:  2012-03

3.  [Driving ability with affective disorders and under psychotropic drugs].

Authors:  G Laux; A Brunnauer
Journal:  Nervenarzt       Date:  2014-07       Impact factor: 1.214

4.  [Driving ability with alcohol and drug dependence and schizophrenia].

Authors:  M Soyka; S Dittert; S Kagerer-Volk; M Soyka
Journal:  Nervenarzt       Date:  2014-07       Impact factor: 1.214

5.  Driving skills in unmedicated first- and recurrent-episode schizophrenic patients.

Authors:  Felix M Segmiller; Verena Buschert; Gerd Laux; N Nedopil; Ulrich Palm; Katharina Furjanic; Peter Zwanzger; Alexander Brunnauer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-10-25       Impact factor: 5.270

Review 6.  Medications and impaired driving.

Authors:  Amanda Hetland; David B Carr
Journal:  Ann Pharmacother       Date:  2014-01-28       Impact factor: 3.154

Review 7.  A review of impaired visual processing and the daily visual world in patients with schizophrenia.

Authors:  Tomohiro Kogata; Tetsuya Iidaka
Journal:  Nagoya J Med Sci       Date:  2018-08       Impact factor: 1.131

8.  Driver assessment service for people with mental illness.

Authors:  Calvin Wc Chiu; Colin Km Law; Andy Sk Cheng
Journal:  Hong Kong J Occup Ther       Date:  2019-11-18       Impact factor: 0.917

9.  Driving Performance Under Treatment of Most Frequently Prescribed Drugs for Mental Disorders: A Systematic Review of Patient Studies.

Authors:  Alexander Brunnauer; Florian Herpich; Peter Zwanzger; Gerd Laux
Journal:  Int J Neuropsychopharmacol       Date:  2021-09-21       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.